173 related articles for article (PubMed ID: 1678695)
1. [Treatment of prolactinoma with a new dopamine agonist].
Svoboda T; Luger A; Knosp E; Geyer G
Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
3. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
[TBL] [Abstract][Full Text] [Related]
4. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of prolactinomas.
Jaquet P
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
[TBL] [Abstract][Full Text] [Related]
6. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
7. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
9. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
11. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
12. [Prolactinoma is more frequent among men than among women. A dopamine agonist is effective in the treatment].
Hulting AL; Muhr C; Lundberg PO; Werner S
Lakartidningen; 1990 Dec; 87(50):4335-7. PubMed ID: 1980709
[No Abstract] [Full Text] [Related]
13. [The best approach to treat prolactinoma].
Zárate A; Saucedo R; Basurto L
Gac Med Mex; 2004; 140(5):567-9. PubMed ID: 15559242
[TBL] [Abstract][Full Text] [Related]
14. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of macroprolactinomas with CV 205-502.
Kvistborg A; Halse J; Bakke S; Bjøro T; Hansen E; Djøseland O; Brownell J; Jervell J
Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
[TBL] [Abstract][Full Text] [Related]
16. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
Grebe SK; Delahunt JW; Feek CM
N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
[TBL] [Abstract][Full Text] [Related]
17. The use of surgery for the treatment of prolactinomas.
van't Verlaat JW
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
[TBL] [Abstract][Full Text] [Related]
18. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
van't Verlaat JW; Croughs RJ; Brownell J
Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
[TBL] [Abstract][Full Text] [Related]
19. CV 205-502 treatment of macroprolactinomas.
Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
[TBL] [Abstract][Full Text] [Related]
20. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]